TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Amazon investors’ patience wears thin
  2. Motoring Q&A: ‘Check engine’ light doesn’t reset itself
  3. Toyota Yaris adds French flair for ’15
  4. Sell-off reins in complacency
  5. Bond mutual funds continue to carry their weight
  6. Mini goes mainstream
  7. First Niagara sets aside $45 million
  8. Stocks rise broadly on earnings; Amazon sinks
  9. Falling fuel prices help airlines — not fliers
  10. Rule to close coal royalty loophole
  11. Education Management removes itself from Nasdaq listing
Subscribe today! Click here for our subscription offers.